{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:05:33Z","timestamp":1788818733040,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.toxlet.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T18:00:11Z","timestamp":1728496811000},"page":"158-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Generation and application of CES1-knockout Tet-Off-regulated CYP3A4 and UGT1A1-expressing Caco-2 cells"],"prefix":"10.1016","volume":"401","author":[{"given":"Michika","family":"Murata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ueyama-Toba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumito","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41556-020-0472-5","article-title":"Fast and efficient generation of knock-in human organoids using homology-independent CRISPR\u2013Cas9 precision genome editing","volume":"22","author":"Artegiani","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.toxlet.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","article-title":"Caco-2 monolayers in experimental and theoretical predictions of drug transport","volume":"46","author":"Artursson","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.toxlet.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0076-6879(02)57690-4","article-title":"Polarized cell cultures for integrated studies of drug metabolism and transport","volume":"357","author":"Brimer-Cline","year":"2002","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.toxlet.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0092-8674(93)80052-G","article-title":"A 5\u2032 element of the chicken \u03b2-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila","volume":"74","author":"Chung","year":"1993","journal-title":"Cell"},{"issue":"80","key":"10.1016\/j.toxlet.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.toxlet.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1023\/A:1016428304366","article-title":"Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4","volume":"13","author":"Crespi","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.toxlet.2024.10.003_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200241040-00001","article-title":"The Mucosa of the small intestine","volume":"41","author":"Doherty","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.toxlet.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1081\/DMR-120000653","article-title":"The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*\u2020","volume":"33","author":"Fisher","year":"2001","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.toxlet.2024.10.003_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.toxlet.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1022359300826","article-title":"Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter","volume":"20","author":"Horie","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.toxlet.2024.10.003_bib11","doi-asserted-by":"crossref","DOI":"10.1023\/A:1018986605929","article-title":"Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase","author":"Hu","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.toxlet.2024.10.003_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91160-z","article-title":"Generation of tetracycline-controllable CYP3A4-expressing Caco-2 cells by the piggyBac transposon system","volume":"11","author":"Ichikawa","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxlet.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1124\/dmd.105.004226","article-title":"Identification of esterases expressed in Caco-2 Cells and effects of their hydrolyzing activity in predicting human intestinal absorption","volume":"33","author":"Imai","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2024.10.003_bib14","first-page":"1185","article-title":"Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption","volume":"33","author":"Imai","year":"2005","journal-title":"Pharmacology"},{"key":"10.1016\/j.toxlet.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2133\/dmpk.21.173","article-title":"Human carboxylesterase isozymes: catalytic properties and rational Drug Design","volume":"21","author":"IMAI","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.toxlet.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1248\/bpb.b17-00880","article-title":"Development of a Caco-2 cell line carrying the human intestine-type CES expression profile as a promising tool for Ester-containing drug permeability studies","volume":"41","author":"Ishizaki","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.toxlet.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.vascn.2014.08.002","article-title":"Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations","volume":"70","author":"Jin","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.toxlet.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2133\/dmpk.DMPK-12-RG-059","article-title":"Establishment of MDCKII cell monolayer with metabolic activity by CYP3A4 transduced with recombinant adenovirus","volume":"28","author":"Kataoka","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.toxlet.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ymthe.2005.04.015","article-title":"Efficient gene transfer into mouse embryonic stem cells with adenovirus vectors","volume":"12","author":"Kawabata","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.toxlet.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1021\/mp200487h","article-title":"Transfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism","volume":"9","author":"Kwatra","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.toxlet.2024.10.003_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-018-0644-7","article-title":"Individualization of Irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics","author":"de Man","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.toxlet.2024.10.003_bib22","first-page":"177","article-title":"Enalapril: a new angiotensin converting enzyme inhibitor","volume":"20","author":"McLeod","year":"1986","journal-title":"Drug Intell. Clin. Pharm."},{"key":"10.1016\/j.toxlet.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/jps.23069","article-title":"Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK\u2013MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2","volume":"101","author":"Mease","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxlet.2024.10.003_bib24","article-title":"Intestinal transport as a potential determinant of drug bioavailability","author":"Nauli","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.toxlet.2024.10.003_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00204-021-03175-0","article-title":"Generation of Caco-2 cells stably expressing CYP3A4\u00b7POR\u00b7UGT1A1 and CYP3A4\u00b7POR\u00b7UGT1A1*6 using a PITCh system","volume":"96","author":"Negoro","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.toxlet.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2133\/dmpk.DMPK-11-RG-034","article-title":"Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data","volume":"26","author":"Nishimuta","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.toxlet.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2024.10.003_bib28","article-title":"Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells","volume":"24","author":"Prueksaritanont","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2024.10.003_bib29","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.toxlet.2024.10.003_bib30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omtm.2023.08.003","article-title":"Establishment of UGT1A1-knockout human iPS-derived hepatic organoids for UGT1A1-specific kinetics and toxicity evaluation","volume":"30","author":"Shintani","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.toxlet.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/17425255.4.4.395","article-title":"The Caco-2 cell monolayer: usefulness and limitations","volume":"4","author":"Sun","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.toxlet.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1093\/nar\/gkx130","article-title":"Highly efficient biallelic genome editing of human ES\/iPS cells using a CRISPR\/Cas9 or TALEN system","volume":"45","author":"Takayama","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.toxlet.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.xphs.2015.11.035","article-title":"Application of a human intestinal epithelial cell monolayer to the prediction of oral drug absorption in humans as a superior alternative to the Caco-2 cell monolayer","volume":"105","author":"Takenaka","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxlet.2024.10.003_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.dmpk.2016.08.004","article-title":"Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates","volume":"32","author":"Takenaka","year":"2017","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.toxlet.2024.10.003_bib35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.lfs.2007.07.026","article-title":"Carboxylesterase in the liver and small intestine of experimental animals and human","volume":"81","author":"Taketani","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.toxlet.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0005-2736(98)00093-5","article-title":"Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter","volume":"1373","author":"Temple","year":"1998","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.toxlet.2024.10.003_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/dmd.113.053512","article-title":"In vitro drug metabolism by human carboxylesterase 1: focus on Angiotensin-converting enzyme inhibitors","volume":"42","author":"Thomsen","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxlet.2024.10.003_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100497","article-title":"Generation of Caco-2 cells with predictable metabolism by CYP3A4, UGT1A1 and CES using the PITCh system","volume":"50","author":"Yamada","year":"2023","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.toxlet.2024.10.003_bib40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jps.10050","article-title":"New and better protocols for a short-term Caco-2 cell culture system","volume":"91","author":"Yamashita","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxlet.2024.10.003_bib41","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1073\/pnas.1008322108","article-title":"A hyperactive piggyBac transposase for mammalian applications","volume":"108","author":"Yusa","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427424020356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427424020356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T01:06:56Z","timestamp":1730336816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427424020356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":41,"alternative-id":["S0378427424020356"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2024.10.003","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation and application of CES1-knockout Tet-Off-regulated CYP3A4 and UGT1A1-expressing Caco-2 cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}